Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT05853575) titled 'Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)' on April 12, 2023.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mirati Therapeutics Inc.
Condition:
Advanced Cancer
Metastatic Cancer
Malignant Neoplasm of Lung
Intervention:
Drug: Adagrasib
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: February 16, 2024
Target Sample Size: 200
Countries of Recruitment:
United States
Brazil
Croatia
France
Greece
Hungary
Israe...